HCM
HUTCHMED (China) Limited
Drug Manufacturers - Specialty & Generic
Market Cap$2.31B
5Y Perf.-38.4%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
HCM vs DBVT
Revenue, margins, valuation, and 5-year total return — side by side.
DBVT
DBV Technologies S.A.
Biotechnology
Market Cap$1721.78T
5Y Perf.-58.6%
HCM vs DBVT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | HCM | DBVT |
|---|---|---|
| Industry | Drug Manufacturers - Specialty & Generic | Biotechnology |
| Market Cap | $2.31B | $1721.78T |
| Revenue (TTM) | $602M | $0.00 |
| Net Income (TTM) | $467M | $-168M |
| Gross Margin | 8.9% | — |
| Operating Margin | -3.3% | — |
| Forward P/E | 42.0x | — |
| Total Debt | $90M | $22M |
| Cash & Equiv. | $154M | $194M |
HCM vs DBVT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
HCM
DBVT
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| HUTCHMED (China) Li… (HCM) | 100 | 61.6 | -38.4% |
| DBV Technologies S.… (DBVT) | 100 | 41.4 | -58.6% |
Price return only. Dividends and distributions are not included.
Quick Verdict: HCM vs DBVT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: HCM leads in 4 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. DBV Technologies S.A. is the stronger pick specifically for recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
HCM
HUTCHMED (China) Limited
The Income Pick
HCM carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- Dividend streak 0 yrs, beta 0.66
- Rev growth -24.8%, EPS growth -63.3%, 3Y rev CAGR 21.0%
- -2.7% 10Y total return vs DBVT's -86.8%
Best for: income & stability and growth exposure
DBVT
DBV Technologies S.A.
The Momentum Pick
DBVT is the clearest fit if your priority is momentum.
- +114.1% vs HCM's -9.6%
Best for: momentum
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | HCM | -24.8% revenue growth vs DBVT's -100.0% |
| Quality / Margins | HCM | 77.5% margin vs DBVT's 0.3% |
| Stability / Safety | HCM | Beta 0.66 vs DBVT's 1.26, lower leverage |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | DBVT | +114.1% vs HCM's -9.6% |
| Efficiency (ROA) | HCM | 30.6% ROA vs DBVT's -89.0% |
HCM vs DBVT — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2023
Segment breakdown not available.
HCM vs DBVT — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLHCMLAGGINGDBVT
DBVTDBV Technologies S.A.
2leads
HCMHUTCHMED (China) Limi…
2leads
6 Total Categories
CATEGORYLEADERvs DBVTMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
HCM1/1
Valuation MetricsMultiples, price ratios, and targets
DBVT2/2
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
HCM5/8
Total Returns1Y, 3Y, 5Y total returns with dividends
DBVT4/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
HCM leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
HCM and DBVT operate at a comparable scale, with $602M and $0 in trailing revenue.
| Metric | HCMHUTCHMED (China) … | DBVTDBV Technologies … |
|---|---|---|
| RevenueTrailing 12 months | $602M | $0 |
| EBITDAEarnings before interest/tax | -$7M | -$112M |
| Net IncomeAfter-tax profit | $467M | -$168M |
| Free Cash FlowCash after capex | -$50M | -$151M |
| Gross MarginGross profit ÷ Revenue | +8.9% | — |
| Operating MarginEBIT ÷ Revenue | -3.3% | — |
| Net MarginNet income ÷ Revenue | +77.5% | — |
| FCF MarginFCF ÷ Revenue | -8.2% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | -9.2% | — |
| EPS Growth (YoY)Latest quarter vs prior year | +16.6% | +91.5% |
HCM leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
DBVT leads this category, winning 2 of 2 comparable metrics.
Valuation Metrics
| Metric | HCMHUTCHMED (China) … | DBVTDBV Technologies … |
|---|---|---|
| Market CapShares × price | $2.3B | $1721.78T |
| Enterprise ValueMkt cap + debt − cash | $2.2B | $1721.78T |
| Trailing P/EPrice ÷ TTM EPS | 61.05x | -0.76x |
| Forward P/EPrice ÷ next-FY EPS est. | 42.03x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 3.66x | — |
| Price / BookPrice ÷ Book value/share | 3.04x | 0.66x |
| Price / FCFMarket cap ÷ FCF | — | — |
DBVT leads this category, winning 2 of 2 comparable metrics.
Profitability & Efficiency
HCM leads this category, winning 5 of 8 comparable metrics.
Profitability & Efficiency
HCM delivers a 46.4% return on equity — every $100 of shareholder capital generates $46 in annual profit, vs $-130 for DBVT. HCM carries lower financial leverage with a 0.12x debt-to-equity ratio, signaling a more conservative balance sheet compared to DBVT's 0.13x. On the Piotroski fundamental quality scale (0–9), DBVT scores 4/9 vs HCM's 3/9, reflecting mixed financial health.
| Metric | HCMHUTCHMED (China) … | DBVTDBV Technologies … |
|---|---|---|
| ROE (TTM)Return on equity | +46.4% | -130.2% |
| ROA (TTM)Return on assets | +30.6% | -89.0% |
| ROICReturn on invested capital | -5.2% | — |
| ROCEReturn on capital employed | -4.9% | -145.7% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 4 |
| Debt / EquityFinancial leverage | 0.12x | 0.13x |
| Net DebtTotal debt minus cash | -$64M | -$172M |
| Cash & Equiv.Liquid assets | $154M | $194M |
| Total DebtShort + long-term debt | $90M | $22M |
| Interest CoverageEBIT ÷ Interest expense | -15.22x | -189.82x |
HCM leads this category, winning 5 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
DBVT leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in HCM five years ago would be worth $4,958 today (with dividends reinvested), compared to $3,344 for DBVT. Over the past 12 months, DBVT leads with a +114.1% total return vs HCM's -9.6%. The 3-year compound annual growth rate (CAGR) favors DBVT at 6.4% vs HCM's -4.7% — a key indicator of consistent wealth creation.
| Metric | HCMHUTCHMED (China) … | DBVTDBV Technologies … |
|---|---|---|
| YTD ReturnYear-to-date | -1.6% | +5.5% |
| 1-Year ReturnPast 12 months | -9.6% | +114.1% |
| 3-Year ReturnCumulative with dividends | -13.5% | +20.4% |
| 5-Year ReturnCumulative with dividends | -50.4% | -66.6% |
| 10-Year ReturnCumulative with dividends | -2.7% | -86.8% |
| CAGR (3Y)Annualised 3-year return | -4.7% | +6.4% |
DBVT leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
Evenly matched — HCM and DBVT each lead in 1 of 2 comparable metrics.
Risk & Volatility
HCM is the less volatile stock with a 0.66 beta — it tends to amplify market swings less than DBVT's 1.26 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. DBVT currently trades 76.8% from its 52-week high vs HCM's 68.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | HCMHUTCHMED (China) … | DBVTDBV Technologies … |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.66x | 1.26x |
| 52-Week HighHighest price in past year | $19.50 | $26.18 |
| 52-Week LowLowest price in past year | $12.91 | $7.53 |
| % of 52W HighCurrent price vs 52-week peak | +68.9% | +76.8% |
| RSI (14)Momentum oscillator 0–100 | 34.2 | 43.8 |
| Avg Volume (50D)Average daily shares traded | 31K | 253K |
Evenly matched — HCM and DBVT each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates HCM as "Buy" and DBVT as "Buy". Consensus price targets imply 130.5% upside for DBVT (target: $46) vs 30.3% for HCM (target: $18).
| Metric | HCMHUTCHMED (China) … | DBVTDBV Technologies … |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $17.50 | $46.33 |
| # AnalystsCovering analysts | 10 | 15 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | 0 | 0 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +1.6% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
HCM leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). DBVT leads in 2 (Valuation Metrics, Total Returns). 1 tied.
Best OverallHUTCHMED (China) Limited (HCM)Leads 2 of 6 categories
Loading custom metrics...
HCM vs DBVT: Frequently Asked Questions
9 questions · data-driven answers · updated daily
01Is HCM or DBVT a better buy right now?
HUTCHMED (China) Limited (HCM) offers the better valuation at 61.
0x trailing P/E (42. 0x forward), making it the more compelling value choice. Analysts rate HUTCHMED (China) Limited (HCM) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — HCM or DBVT?
Over the past 5 years, HUTCHMED (China) Limited (HCM) delivered a total return of -50.
4%, compared to -66. 6% for DBV Technologies S. A. (DBVT). Over 10 years, the gap is even starker: HCM returned -2. 7% versus DBVT's -86. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — HCM or DBVT?
By beta (market sensitivity over 5 years), HUTCHMED (China) Limited (HCM) is the lower-risk stock at 0.
66β versus DBV Technologies S. A. 's 1. 26β — meaning DBVT is approximately 90% more volatile than HCM relative to the S&P 500. On balance sheet safety, HUTCHMED (China) Limited (HCM) carries a lower debt/equity ratio of 12% versus 13% for DBV Technologies S. A. — giving it more financial flexibility in a downturn.
04Which is growing faster — HCM or DBVT?
On earnings-per-share growth, the picture is similar: HUTCHMED (China) Limited grew EPS -63.
3% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — HCM or DBVT?
HUTCHMED (China) Limited (HCM) is the more profitable company, earning 6.
0% net margin versus 0. 0% for DBV Technologies S. A. — meaning it keeps 6. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: DBVT leads at 0. 0% versus -6. 9% for HCM. At the gross margin level — before operating expenses — HCM leads at 44. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is HCM or DBVT more undervalued right now?
Analyst consensus price targets imply the most upside for DBVT: 130.
5% to $46. 33.
07Which pays a better dividend — HCM or DBVT?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
08Is HCM or DBVT better for a retirement portfolio?
For long-horizon retirement investors, HUTCHMED (China) Limited (HCM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
66)). Both have compounded well over 10 years (HCM: -2. 7%, DBVT: -86. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between HCM and DBVT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.